热流生物科学公司完成了对GF-1002的犬子基因治疗试验,GF-1002是SIRT6的治疗,没有任何不良事件和安全得到确认。 Genflow Biosciences finished dosing its canine gene therapy trial for GF-1002, a SIRT6-based treatment, with no adverse events and safety confirmed.

基因流生物科学已完成了对以SIRT6为基础的治疗的犬子基因疗法试验的剂量,所有狗都接受了全剂量治疗,没有报告任何不良事件,表明非常安全。 Genflow Biosciences has completed dosing in its canine gene therapy trial for a SIRT6-based treatment, with all dogs receiving the full dose and no adverse events reported, indicating strong safety. 持续进行的盲目审判始于2025年3月,旨在评估该疗法对健康泛度和与年龄有关的状况(如sarcopenia)的影响。 The ongoing, blinded trial, started in March 2025, aims to assess the therapy’s impact on healthspan and age-related conditions like sarcopenia. 预计2026年1月中至晚期取得初步效果结果,2026年6月至7月有后续数据。 Initial efficacy results are expected in mid-to-late January 2026, with follow-up data in June-July 2026. 治疗法GF-1002 提供了SIRT6基因的百年变种。 The therapy, GF-1002, delivers a centenarian variant of the SIRT6 gene. 源流计划,在数据审查后,与动物健康伙伴探讨颁发许可证事宜,并正在研究代谢性肝病的治疗。 Genflow plans to explore licensing with animal health partners after data review and is also studying the treatment for metabolic liver disease.